Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06662097 · ClinicalTrials.gov registry record · Phase 2

A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery

A Phase 2 study of Surgery and Nerve Injury, sponsored by Alume Biosciences.

Recruiting
Registry status
Phase 2
Development phase
64
Enrollment target
1
Study location

NCT06662097 is a Phase 2 study of Surgery and Nerve Injury that is actively recruiting participants, run by Alume Biosciences. The registered enrollment target is 64 participants, below the 52,851-participant average among 120 other Surgery trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06662097, a Phase 2 study of Surgery and Nerve Injury, is actively recruiting participants, sponsored by Alume Biosciences.

RECRUITING
Registry status
Phase 2
Development phase
64 participants
Enrollment target
1
Study location

Study Summary

Feasibility study of Bevonescein to highlight Nerves and Ureter in patients undergoing Minimally Invasive Surgery

Interventions

  • DRUG Bevonescein

Study Locations (1)

California

  • University of California San Diego - San Diego

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2024-10-16
Est. Completion 2025-09
Phase Phase 2

Sponsor

Alume Biosciences

4 total trials

What the Registry Record Tells You About NCT06662097

The ClinicalTrials.gov registry entry for NCT06662097 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 52,851-participant average among 120 other Surgery trials with a reported enrollment target (100% lower). The listed sponsor is Alume Biosciences, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Surgery appearing as the primary indexed condition, and to 1 intervention - of which Bevonescein is the first listed.

NCT06662097 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06662097 about?

NCT06662097 is a clinical study titled "A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery". Feasibility study of Bevonescein to highlight Nerves and Ureter in patients undergoing Minimally Invasive Surgery

What is the current status of trial NCT06662097?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2024-10-16. Estimated completion is 2025-09.

What conditions does trial NCT06662097 study?

This clinical trial studies the following conditions: Surgery, Nerve Injury, Imaging.

What interventions are being tested in trial NCT06662097?

The interventions under investigation include: Bevonescein (DRUG).

Who is sponsoring clinical trial NCT06662097?

This trial is sponsored by Alume Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06662097 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Surgery

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.